nodes	percent_of_prediction	percent_of_DWPC	metapath
Prazosin—ABCG2—Rosuvastatin—atherosclerosis	0.14	0.235	CbGbCtD
Prazosin—ABCG2—Ezetimibe—atherosclerosis	0.14	0.235	CbGbCtD
Prazosin—ABCG2—Pravastatin—atherosclerosis	0.128	0.213	CbGbCtD
Prazosin—ABCB1—Ezetimibe—atherosclerosis	0.0506	0.0846	CbGbCtD
Prazosin—ABCB1—Simvastatin—atherosclerosis	0.0471	0.0787	CbGbCtD
Prazosin—ABCB1—Pravastatin—atherosclerosis	0.046	0.077	CbGbCtD
Prazosin—ABCB1—Lovastatin—atherosclerosis	0.046	0.077	CbGbCtD
Prazosin—Antinuclear antibody positive—Lovastatin—atherosclerosis	0.0135	0.0539	CcSEcCtD
Prazosin—Antinuclear antibody positive—Simvastatin—atherosclerosis	0.0126	0.0504	CcSEcCtD
Prazosin—Antinuclear antibody positive—Pravastatin—atherosclerosis	0.0114	0.0456	CcSEcCtD
Prazosin—Gynaecomastia—Rosuvastatin—atherosclerosis	0.00324	0.0129	CcSEcCtD
Prazosin—Cataract—Lovastatin—atherosclerosis	0.00322	0.0129	CcSEcCtD
Prazosin—Vasculitis—Lovastatin—atherosclerosis	0.00315	0.0125	CcSEcCtD
Prazosin—Vasculitis—Ezetimibe—atherosclerosis	0.00308	0.0123	CcSEcCtD
Prazosin—Cataract—Simvastatin—atherosclerosis	0.00302	0.012	CcSEcCtD
Prazosin—Vasculitis—Simvastatin—atherosclerosis	0.00294	0.0117	CcSEcCtD
Prazosin—Gynaecomastia—Lovastatin—atherosclerosis	0.00275	0.011	CcSEcCtD
Prazosin—Cataract—Pravastatin—atherosclerosis	0.00273	0.0109	CcSEcCtD
Prazosin—Vasculitis—Pravastatin—atherosclerosis	0.00266	0.0106	CcSEcCtD
Prazosin—Gynaecomastia—Simvastatin—atherosclerosis	0.00257	0.0102	CcSEcCtD
Prazosin—Gynaecomastia—Pravastatin—atherosclerosis	0.00232	0.00926	CcSEcCtD
Prazosin—Pancreatitis—Rosuvastatin—atherosclerosis	0.00223	0.00889	CcSEcCtD
Prazosin—Pancreatitis—Lovastatin—atherosclerosis	0.00189	0.00753	CcSEcCtD
Prazosin—Pancreatitis—Ezetimibe—atherosclerosis	0.00185	0.00739	CcSEcCtD
Prazosin—Abdominal discomfort—Lovastatin—atherosclerosis	0.00185	0.00736	CcSEcCtD
Prazosin—Erectile dysfunction—Lovastatin—atherosclerosis	0.00177	0.00708	CcSEcCtD
Prazosin—Pancreatitis—Simvastatin—atherosclerosis	0.00177	0.00704	CcSEcCtD
Prazosin—Orthostatic hypotension—Niacin—atherosclerosis	0.00175	0.00697	CcSEcCtD
Prazosin—Erectile dysfunction—Ezetimibe—atherosclerosis	0.00174	0.00694	CcSEcCtD
Prazosin—Abdominal discomfort—Simvastatin—atherosclerosis	0.00173	0.00689	CcSEcCtD
Prazosin—Erectile dysfunction—Simvastatin—atherosclerosis	0.00166	0.00662	CcSEcCtD
Prazosin—Angina pectoris—Niacin—atherosclerosis	0.00161	0.00643	CcSEcCtD
Prazosin—Pancreatitis—Pravastatin—atherosclerosis	0.0016	0.00637	CcSEcCtD
Prazosin—Sweating increased—Pravastatin—atherosclerosis	0.00159	0.00633	CcSEcCtD
Prazosin—Angina pectoris—Pravastatin—atherosclerosis	0.00159	0.00633	CcSEcCtD
Prazosin—Erectile dysfunction—Niacin—atherosclerosis	0.00152	0.00608	CcSEcCtD
Prazosin—Erectile dysfunction—Pravastatin—atherosclerosis	0.0015	0.00598	CcSEcCtD
Prazosin—Flushing—Lovastatin—atherosclerosis	0.00143	0.00571	CcSEcCtD
Prazosin—Flushing—Ezetimibe—atherosclerosis	0.0014	0.0056	CcSEcCtD
Prazosin—Alopecia—Lovastatin—atherosclerosis	0.00136	0.00543	CcSEcCtD
Prazosin—Arthralgia—Rosuvastatin—atherosclerosis	0.00135	0.00538	CcSEcCtD
Prazosin—Flushing—Simvastatin—atherosclerosis	0.00134	0.00534	CcSEcCtD
Prazosin—Alopecia—Ezetimibe—atherosclerosis	0.00134	0.00533	CcSEcCtD
Prazosin—Alopecia—Simvastatin—atherosclerosis	0.00127	0.00508	CcSEcCtD
Prazosin—Vision blurred—Lovastatin—atherosclerosis	0.00126	0.00504	CcSEcCtD
Prazosin—Ill-defined disorder—Lovastatin—atherosclerosis	0.00125	0.00497	CcSEcCtD
Prazosin—Tinnitus—Niacin—atherosclerosis	0.00123	0.00492	CcSEcCtD
Prazosin—Flushing—Niacin—atherosclerosis	0.00123	0.0049	CcSEcCtD
Prazosin—Ill-defined disorder—Ezetimibe—atherosclerosis	0.00122	0.00487	CcSEcCtD
Prazosin—Tinnitus—Pravastatin—atherosclerosis	0.00122	0.00485	CcSEcCtD
Prazosin—Malaise—Lovastatin—atherosclerosis	0.00121	0.00483	CcSEcCtD
Prazosin—Flushing—Pravastatin—atherosclerosis	0.00121	0.00483	CcSEcCtD
Prazosin—Vertigo—Lovastatin—atherosclerosis	0.00121	0.00481	CcSEcCtD
Prazosin—Malaise—Ezetimibe—atherosclerosis	0.00119	0.00473	CcSEcCtD
Prazosin—Vision blurred—Simvastatin—atherosclerosis	0.00118	0.00472	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00118	0.0047	CcSEcCtD
Prazosin—Alopecia—Niacin—atherosclerosis	0.00117	0.00467	CcSEcCtD
Prazosin—Insomnia—Rosuvastatin—atherosclerosis	0.00117	0.00466	CcSEcCtD
Prazosin—Ill-defined disorder—Simvastatin—atherosclerosis	0.00116	0.00465	CcSEcCtD
Prazosin—Palpitations—Ezetimibe—atherosclerosis	0.00116	0.00464	CcSEcCtD
Prazosin—Paraesthesia—Rosuvastatin—atherosclerosis	0.00116	0.00463	CcSEcCtD
Prazosin—Alopecia—Pravastatin—atherosclerosis	0.00115	0.00459	CcSEcCtD
Prazosin—Arthralgia—Lovastatin—atherosclerosis	0.00114	0.00456	CcSEcCtD
Prazosin—Malaise—Simvastatin—atherosclerosis	0.00113	0.00452	CcSEcCtD
Prazosin—Tension—Niacin—atherosclerosis	0.00113	0.00451	CcSEcCtD
Prazosin—Discomfort—Lovastatin—atherosclerosis	0.00113	0.0045	CcSEcCtD
Prazosin—Vertigo—Simvastatin—atherosclerosis	0.00113	0.0045	CcSEcCtD
Prazosin—Arthralgia—Ezetimibe—atherosclerosis	0.00112	0.00447	CcSEcCtD
Prazosin—Nervousness—Niacin—atherosclerosis	0.00112	0.00447	CcSEcCtD
Prazosin—Dry mouth—Lovastatin—atherosclerosis	0.00112	0.00446	CcSEcCtD
Prazosin—Tension—Pravastatin—atherosclerosis	0.00111	0.00444	CcSEcCtD
Prazosin—Discomfort—Ezetimibe—atherosclerosis	0.00111	0.00442	CcSEcCtD
Prazosin—Pain—Rosuvastatin—atherosclerosis	0.00111	0.00441	CcSEcCtD
Prazosin—Constipation—Rosuvastatin—atherosclerosis	0.00111	0.00441	CcSEcCtD
Prazosin—Nervousness—Pravastatin—atherosclerosis	0.0011	0.0044	CcSEcCtD
Prazosin—Dry mouth—Ezetimibe—atherosclerosis	0.0011	0.00437	CcSEcCtD
Prazosin—Vision blurred—Niacin—atherosclerosis	0.00109	0.00433	CcSEcCtD
Prazosin—Vision blurred—Pravastatin—atherosclerosis	0.00107	0.00427	CcSEcCtD
Prazosin—Arthralgia—Simvastatin—atherosclerosis	0.00107	0.00426	CcSEcCtD
Prazosin—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00106	0.00425	CcSEcCtD
Prazosin—Discomfort—Simvastatin—atherosclerosis	0.00106	0.00421	CcSEcCtD
Prazosin—Ill-defined disorder—Pravastatin—atherosclerosis	0.00105	0.0042	CcSEcCtD
Prazosin—Vertigo—Niacin—atherosclerosis	0.00104	0.00413	CcSEcCtD
Prazosin—Syncope—Niacin—atherosclerosis	0.00103	0.00412	CcSEcCtD
Prazosin—Urticaria—Rosuvastatin—atherosclerosis	0.00103	0.0041	CcSEcCtD
Prazosin—Oedema—Simvastatin—atherosclerosis	0.00102	0.00409	CcSEcCtD
Prazosin—Malaise—Pravastatin—atherosclerosis	0.00102	0.00408	CcSEcCtD
Prazosin—Vertigo—Pravastatin—atherosclerosis	0.00102	0.00407	CcSEcCtD
Prazosin—Palpitations—Niacin—atherosclerosis	0.00102	0.00406	CcSEcCtD
Prazosin—Loss of consciousness—Niacin—atherosclerosis	0.00101	0.00404	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000998	0.00398	CcSEcCtD
Prazosin—Insomnia—Lovastatin—atherosclerosis	0.000991	0.00395	CcSEcCtD
Prazosin—Paraesthesia—Lovastatin—atherosclerosis	0.000983	0.00392	CcSEcCtD
Prazosin—Arthralgia—Niacin—atherosclerosis	0.000981	0.00391	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000979	0.0039	CcSEcCtD
Prazosin—Dyspnoea—Lovastatin—atherosclerosis	0.000976	0.00389	CcSEcCtD
Prazosin—Insomnia—Ezetimibe—atherosclerosis	0.000972	0.00388	CcSEcCtD
Prazosin—Arthralgia—Pravastatin—atherosclerosis	0.000966	0.00385	CcSEcCtD
Prazosin—Paraesthesia—Ezetimibe—atherosclerosis	0.000965	0.00385	CcSEcCtD
Prazosin—Dry mouth—Niacin—atherosclerosis	0.00096	0.00383	CcSEcCtD
Prazosin—Dyspnoea—Ezetimibe—atherosclerosis	0.000958	0.00382	CcSEcCtD
Prazosin—Discomfort—Pravastatin—atherosclerosis	0.000955	0.00381	CcSEcCtD
Prazosin—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000952	0.0038	CcSEcCtD
Prazosin—Fatigue—Lovastatin—atherosclerosis	0.000944	0.00377	CcSEcCtD
Prazosin—Oedema—Niacin—atherosclerosis	0.000941	0.00375	CcSEcCtD
Prazosin—Pain—Lovastatin—atherosclerosis	0.000937	0.00374	CcSEcCtD
Prazosin—Constipation—Lovastatin—atherosclerosis	0.000937	0.00374	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000933	0.00372	CcSEcCtD
Prazosin—Asthenia—Rosuvastatin—atherosclerosis	0.000927	0.0037	CcSEcCtD
Prazosin—Insomnia—Simvastatin—atherosclerosis	0.000927	0.0037	CcSEcCtD
Prazosin—Oedema—Pravastatin—atherosclerosis	0.000926	0.00369	CcSEcCtD
Prazosin—Fatigue—Ezetimibe—atherosclerosis	0.000926	0.00369	CcSEcCtD
Prazosin—Shock—Niacin—atherosclerosis	0.000925	0.00369	CcSEcCtD
Prazosin—Paraesthesia—Simvastatin—atherosclerosis	0.00092	0.00367	CcSEcCtD
Prazosin—Constipation—Ezetimibe—atherosclerosis	0.000919	0.00366	CcSEcCtD
Prazosin—Pain—Ezetimibe—atherosclerosis	0.000919	0.00366	CcSEcCtD
Prazosin—Tachycardia—Niacin—atherosclerosis	0.000918	0.00366	CcSEcCtD
Prazosin—Pruritus—Rosuvastatin—atherosclerosis	0.000914	0.00365	CcSEcCtD
Prazosin—Dyspnoea—Simvastatin—atherosclerosis	0.000913	0.00364	CcSEcCtD
Prazosin—Hyperhidrosis—Niacin—atherosclerosis	0.000909	0.00363	CcSEcCtD
Prazosin—Feeling abnormal—Lovastatin—atherosclerosis	0.000903	0.0036	CcSEcCtD
Prazosin—Hyperhidrosis—Pravastatin—atherosclerosis	0.000895	0.00357	CcSEcCtD
Prazosin—Feeling abnormal—Ezetimibe—atherosclerosis	0.000885	0.00353	CcSEcCtD
Prazosin—Diarrhoea—Rosuvastatin—atherosclerosis	0.000884	0.00353	CcSEcCtD
Prazosin—Fatigue—Simvastatin—atherosclerosis	0.000883	0.00352	CcSEcCtD
Prazosin—Constipation—Simvastatin—atherosclerosis	0.000876	0.00349	CcSEcCtD
Prazosin—Pain—Simvastatin—atherosclerosis	0.000876	0.00349	CcSEcCtD
Prazosin—Urticaria—Lovastatin—atherosclerosis	0.00087	0.00347	CcSEcCtD
Prazosin—Body temperature increased—Lovastatin—atherosclerosis	0.000866	0.00345	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000857	0.00342	CcSEcCtD
Prazosin—Dizziness—Rosuvastatin—atherosclerosis	0.000855	0.00341	CcSEcCtD
Prazosin—Urticaria—Ezetimibe—atherosclerosis	0.000853	0.0034	CcSEcCtD
Prazosin—Insomnia—Niacin—atherosclerosis	0.000851	0.00339	CcSEcCtD
Prazosin—Body temperature increased—Ezetimibe—atherosclerosis	0.000849	0.00339	CcSEcCtD
Prazosin—Paraesthesia—Niacin—atherosclerosis	0.000845	0.00337	CcSEcCtD
Prazosin—Feeling abnormal—Simvastatin—atherosclerosis	0.000844	0.00337	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000844	0.00337	CcSEcCtD
Prazosin—Dyspnoea—Niacin—atherosclerosis	0.000839	0.00335	CcSEcCtD
Prazosin—Insomnia—Pravastatin—atherosclerosis	0.000838	0.00334	CcSEcCtD
Prazosin—Somnolence—Niacin—atherosclerosis	0.000836	0.00334	CcSEcCtD
Prazosin—Paraesthesia—Pravastatin—atherosclerosis	0.000832	0.00332	CcSEcCtD
Prazosin—Dyspnoea—Pravastatin—atherosclerosis	0.000826	0.00329	CcSEcCtD
Prazosin—Rash—Rosuvastatin—atherosclerosis	0.000815	0.00325	CcSEcCtD
Prazosin—Dermatitis—Rosuvastatin—atherosclerosis	0.000814	0.00325	CcSEcCtD
Prazosin—Urticaria—Simvastatin—atherosclerosis	0.000814	0.00325	CcSEcCtD
Prazosin—Body temperature increased—Simvastatin—atherosclerosis	0.00081	0.00323	CcSEcCtD
Prazosin—Headache—Rosuvastatin—atherosclerosis	0.00081	0.00323	CcSEcCtD
Prazosin—Hypersensitivity—Lovastatin—atherosclerosis	0.000807	0.00322	CcSEcCtD
Prazosin—Pain—Niacin—atherosclerosis	0.000804	0.00321	CcSEcCtD
Prazosin—Fatigue—Pravastatin—atherosclerosis	0.000798	0.00319	CcSEcCtD
Prazosin—Constipation—Pravastatin—atherosclerosis	0.000792	0.00316	CcSEcCtD
Prazosin—Pain—Pravastatin—atherosclerosis	0.000792	0.00316	CcSEcCtD
Prazosin—Hypersensitivity—Ezetimibe—atherosclerosis	0.000791	0.00316	CcSEcCtD
Prazosin—Asthenia—Lovastatin—atherosclerosis	0.000786	0.00313	CcSEcCtD
Prazosin—Pruritus—Lovastatin—atherosclerosis	0.000775	0.00309	CcSEcCtD
Prazosin—Asthenia—Ezetimibe—atherosclerosis	0.000771	0.00307	CcSEcCtD
Prazosin—Nausea—Rosuvastatin—atherosclerosis	0.000768	0.00306	CcSEcCtD
Prazosin—Feeling abnormal—Pravastatin—atherosclerosis	0.000763	0.00304	CcSEcCtD
Prazosin—Pruritus—Ezetimibe—atherosclerosis	0.00076	0.00303	CcSEcCtD
Prazosin—Hypersensitivity—Simvastatin—atherosclerosis	0.000755	0.00301	CcSEcCtD
Prazosin—Diarrhoea—Lovastatin—atherosclerosis	0.000749	0.00299	CcSEcCtD
Prazosin—Urticaria—Niacin—atherosclerosis	0.000747	0.00298	CcSEcCtD
Prazosin—Body temperature increased—Niacin—atherosclerosis	0.000744	0.00297	CcSEcCtD
Prazosin—Urticaria—Pravastatin—atherosclerosis	0.000736	0.00293	CcSEcCtD
Prazosin—Asthenia—Simvastatin—atherosclerosis	0.000735	0.00293	CcSEcCtD
Prazosin—Diarrhoea—Ezetimibe—atherosclerosis	0.000735	0.00293	CcSEcCtD
Prazosin—Body temperature increased—Pravastatin—atherosclerosis	0.000732	0.00292	CcSEcCtD
Prazosin—Pruritus—Simvastatin—atherosclerosis	0.000725	0.00289	CcSEcCtD
Prazosin—Dizziness—Lovastatin—atherosclerosis	0.000724	0.00289	CcSEcCtD
Prazosin—Dizziness—Ezetimibe—atherosclerosis	0.00071	0.00283	CcSEcCtD
Prazosin—Diarrhoea—Simvastatin—atherosclerosis	0.000701	0.0028	CcSEcCtD
Prazosin—Vomiting—Lovastatin—atherosclerosis	0.000696	0.00278	CcSEcCtD
Prazosin—Hypersensitivity—Niacin—atherosclerosis	0.000693	0.00276	CcSEcCtD
Prazosin—Rash—Lovastatin—atherosclerosis	0.000691	0.00275	CcSEcCtD
Prazosin—Dermatitis—Lovastatin—atherosclerosis	0.00069	0.00275	CcSEcCtD
Prazosin—Headache—Lovastatin—atherosclerosis	0.000686	0.00274	CcSEcCtD
Prazosin—Vomiting—Ezetimibe—atherosclerosis	0.000683	0.00272	CcSEcCtD
Prazosin—Hypersensitivity—Pravastatin—atherosclerosis	0.000682	0.00272	CcSEcCtD
Prazosin—Dizziness—Simvastatin—atherosclerosis	0.000677	0.0027	CcSEcCtD
Prazosin—Rash—Ezetimibe—atherosclerosis	0.000677	0.0027	CcSEcCtD
Prazosin—Dermatitis—Ezetimibe—atherosclerosis	0.000677	0.0027	CcSEcCtD
Prazosin—Asthenia—Niacin—atherosclerosis	0.000675	0.00269	CcSEcCtD
Prazosin—Headache—Ezetimibe—atherosclerosis	0.000673	0.00268	CcSEcCtD
Prazosin—Pruritus—Niacin—atherosclerosis	0.000665	0.00265	CcSEcCtD
Prazosin—Asthenia—Pravastatin—atherosclerosis	0.000664	0.00265	CcSEcCtD
Prazosin—Pruritus—Pravastatin—atherosclerosis	0.000655	0.00261	CcSEcCtD
Prazosin—Vomiting—Simvastatin—atherosclerosis	0.000651	0.0026	CcSEcCtD
Prazosin—Nausea—Lovastatin—atherosclerosis	0.000651	0.00259	CcSEcCtD
Prazosin—Rash—Simvastatin—atherosclerosis	0.000646	0.00258	CcSEcCtD
Prazosin—Dermatitis—Simvastatin—atherosclerosis	0.000645	0.00257	CcSEcCtD
Prazosin—Diarrhoea—Niacin—atherosclerosis	0.000644	0.00257	CcSEcCtD
Prazosin—Headache—Simvastatin—atherosclerosis	0.000642	0.00256	CcSEcCtD
Prazosin—Nausea—Ezetimibe—atherosclerosis	0.000638	0.00255	CcSEcCtD
Prazosin—Diarrhoea—Pravastatin—atherosclerosis	0.000634	0.00253	CcSEcCtD
Prazosin—Dizziness—Niacin—atherosclerosis	0.000622	0.00248	CcSEcCtD
Prazosin—Dizziness—Pravastatin—atherosclerosis	0.000612	0.00244	CcSEcCtD
Prazosin—Nausea—Simvastatin—atherosclerosis	0.000608	0.00243	CcSEcCtD
Prazosin—Vomiting—Niacin—atherosclerosis	0.000598	0.00239	CcSEcCtD
Prazosin—Rash—Niacin—atherosclerosis	0.000593	0.00237	CcSEcCtD
Prazosin—Dermatitis—Niacin—atherosclerosis	0.000593	0.00236	CcSEcCtD
Prazosin—Headache—Niacin—atherosclerosis	0.000589	0.00235	CcSEcCtD
Prazosin—Vomiting—Pravastatin—atherosclerosis	0.000589	0.00235	CcSEcCtD
Prazosin—Rash—Pravastatin—atherosclerosis	0.000584	0.00233	CcSEcCtD
Prazosin—Dermatitis—Pravastatin—atherosclerosis	0.000583	0.00233	CcSEcCtD
Prazosin—Headache—Pravastatin—atherosclerosis	0.00058	0.00231	CcSEcCtD
Prazosin—Nausea—Niacin—atherosclerosis	0.000559	0.00223	CcSEcCtD
Prazosin—Nausea—Pravastatin—atherosclerosis	0.00055	0.00219	CcSEcCtD
Prazosin—ADRA2B—Signaling Pathways—APOA1—atherosclerosis	1.29e-05	8.55e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—AGT—atherosclerosis	1.29e-05	8.52e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—APOB—atherosclerosis	1.28e-05	8.49e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—INS—atherosclerosis	1.28e-05	8.49e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MMP3—atherosclerosis	1.28e-05	8.49e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IGF2—atherosclerosis	1.28e-05	8.45e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—MTHFR—atherosclerosis	1.27e-05	8.43e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—LPL—atherosclerosis	1.27e-05	8.43e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—NOS3—atherosclerosis	1.27e-05	8.39e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PIK3CG—atherosclerosis	1.26e-05	8.36e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—LEP—atherosclerosis	1.26e-05	8.35e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—APOE—atherosclerosis	1.26e-05	8.35e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PDGFB—atherosclerosis	1.26e-05	8.32e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—MAPK3—atherosclerosis	1.25e-05	8.28e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CAV1—atherosclerosis	1.25e-05	8.28e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PPARA—atherosclerosis	1.25e-05	8.27e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—GSTM1—atherosclerosis	1.25e-05	8.26e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—ESR1—atherosclerosis	1.25e-05	8.26e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—APOA1—atherosclerosis	1.25e-05	8.26e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—ABCA1—atherosclerosis	1.25e-05	8.25e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—APOB—atherosclerosis	1.24e-05	8.2e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PRKCG—atherosclerosis	1.24e-05	8.2e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—INS—atherosclerosis	1.24e-05	8.19e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—F2—atherosclerosis	1.23e-05	8.16e-05	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—CXCL8—atherosclerosis	1.23e-05	8.13e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—AGT—atherosclerosis	1.23e-05	8.12e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—LPL—atherosclerosis	1.22e-05	8.11e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—EDN1—atherosclerosis	1.22e-05	8.07e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PPARG—atherosclerosis	1.22e-05	8.07e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CCL2—atherosclerosis	1.22e-05	8.06e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—AGT—atherosclerosis	1.21e-05	8.01e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CCL5—atherosclerosis	1.21e-05	8.01e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—SPP1—atherosclerosis	1.21e-05	7.98e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—ESR1—atherosclerosis	1.2e-05	7.97e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—APOE—atherosclerosis	1.2e-05	7.95e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—LEP—atherosclerosis	1.2e-05	7.95e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—CXCL8—atherosclerosis	1.2e-05	7.95e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—IGF1—atherosclerosis	1.2e-05	7.92e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—INS—atherosclerosis	1.2e-05	7.91e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—GPX1—atherosclerosis	1.2e-05	7.91e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CAV1—atherosclerosis	1.19e-05	7.88e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—F2—atherosclerosis	1.19e-05	7.88e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—ALB—atherosclerosis	1.19e-05	7.86e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—APOA1—atherosclerosis	1.19e-05	7.86e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—APOE—atherosclerosis	1.19e-05	7.85e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—LPL—atherosclerosis	1.18e-05	7.83e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PIK3CG—atherosclerosis	1.18e-05	7.81e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—ALB—atherosclerosis	1.18e-05	7.78e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—CAV1—atherosclerosis	1.18e-05	7.78e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—APOA1—atherosclerosis	1.17e-05	7.76e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—CD36—atherosclerosis	1.16e-05	7.7e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PRKCG—atherosclerosis	1.15e-05	7.61e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—ESR1—atherosclerosis	1.15e-05	7.59e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PIK3CG—atherosclerosis	1.14e-05	7.54e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—NOS3—atherosclerosis	1.14e-05	7.52e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—SERPINE1—atherosclerosis	1.14e-05	7.52e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—F2—atherosclerosis	1.13e-05	7.5e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—MAPK3—atherosclerosis	1.13e-05	7.48e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—NOS3—atherosclerosis	1.12e-05	7.44e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—CXCL8—atherosclerosis	1.12e-05	7.44e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—SPP1—atherosclerosis	1.12e-05	7.42e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—INS—atherosclerosis	1.12e-05	7.39e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PDGFB—atherosclerosis	1.12e-05	7.39e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—CXCL8—atherosclerosis	1.12e-05	7.38e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—MTHFR—atherosclerosis	1.1e-05	7.3e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CCL2—atherosclerosis	1.1e-05	7.27e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—ALB—atherosclerosis	1.1e-05	7.25e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—MAPK3—atherosclerosis	1.09e-05	7.22e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—AGT—atherosclerosis	1.09e-05	7.21e-05	CbGpPWpGaD
Prazosin—HTR1D—GPCR downstream signaling—AKT1—atherosclerosis	1.09e-05	7.19e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—NOS3—atherosclerosis	1.08e-05	7.18e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PIK3CG—atherosclerosis	1.08e-05	7.18e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PPARA—atherosclerosis	1.08e-05	7.16e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—IGF1—atherosclerosis	1.08e-05	7.15e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—INS—atherosclerosis	1.08e-05	7.14e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PIK3CG—atherosclerosis	1.07e-05	7.09e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—HMOX1—atherosclerosis	1.07e-05	7.08e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling by GPCR—IL6—atherosclerosis	1.07e-05	7.08e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—APOE—atherosclerosis	1.07e-05	7.07e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—LEP—atherosclerosis	1.07e-05	7.07e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CCL2—atherosclerosis	1.06e-05	7.02e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CAV1—atherosclerosis	1.06e-05	7e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—APOA1—atherosclerosis	1.06e-05	6.98e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—NOS3—atherosclerosis	1.05e-05	6.94e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—AGT—atherosclerosis	1.05e-05	6.94e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—IGF1—atherosclerosis	1.04e-05	6.9e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—PTGS2—atherosclerosis	1.04e-05	6.88e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—MAPK3—atherosclerosis	1.04e-05	6.87e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PDGFB—atherosclerosis	1.04e-05	6.86e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PPARG—atherosclerosis	1.03e-05	6.84e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—PTGS2—atherosclerosis	1.03e-05	6.81e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—APOE—atherosclerosis	1.03e-05	6.8e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—INS—atherosclerosis	1.03e-05	6.8e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—SERPINE1—atherosclerosis	1.03e-05	6.79e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—APOB—atherosclerosis	1.02e-05	6.78e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—ESR1—atherosclerosis	1.02e-05	6.75e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—CAV1—atherosclerosis	1.02e-05	6.73e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MMP9—atherosclerosis	1.02e-05	6.73e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—APOA1—atherosclerosis	1.02e-05	6.72e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—INS—atherosclerosis	1.01e-05	6.71e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—AGT—atherosclerosis	1.01e-05	6.7e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CCL2—atherosclerosis	1.01e-05	6.69e-05	CbGpPWpGaD
Prazosin—ADRA2A—Hemostasis—AKT1—atherosclerosis	1.01e-05	6.67e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—F2—atherosclerosis	1.01e-05	6.66e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—NFKB1—atherosclerosis	1.01e-05	6.66e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—GSTM1—atherosclerosis	9.97e-06	6.6e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—IGF1—atherosclerosis	9.93e-06	6.57e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—LEP—atherosclerosis	9.92e-06	6.56e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—APOE—atherosclerosis	9.92e-06	6.56e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—SERPINE1—atherosclerosis	9.9e-06	6.55e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MAPK8—atherosclerosis	9.89e-06	6.55e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling by GPCR—AKT1—atherosclerosis	9.86e-06	6.53e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CAV1—atherosclerosis	9.83e-06	6.5e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—APOA1—atherosclerosis	9.8e-06	6.49e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—NOS3—atherosclerosis	9.79e-06	6.48e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—LPL—atherosclerosis	9.78e-06	6.48e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CG—atherosclerosis	9.63e-06	6.38e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CXCL8—atherosclerosis	9.62e-06	6.37e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PTGS2—atherosclerosis	9.59e-06	6.35e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—GPX1—atherosclerosis	9.55e-06	6.32e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—ESR1—atherosclerosis	9.47e-06	6.27e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—NOS3—atherosclerosis	9.45e-06	6.26e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—SERPINE1—atherosclerosis	9.43e-06	6.24e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—F2—atherosclerosis	9.35e-06	6.19e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—CD36—atherosclerosis	9.3e-06	6.15e-05	CbGpPWpGaD
Prazosin—ADRA1D—GPCR downstream signaling—AKT1—atherosclerosis	9.29e-06	6.15e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—ALB—atherosclerosis	9.29e-06	6.15e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CG—atherosclerosis	9.27e-06	6.13e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—MAPK3—atherosclerosis	9.22e-06	6.11e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—IL6—atherosclerosis	9.15e-06	6.06e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—VEGFA—atherosclerosis	9.13e-06	6.04e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—INS—atherosclerosis	9.12e-06	6.04e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—STAT3—atherosclerosis	9.04e-06	5.98e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—NOS3—atherosclerosis	9e-06	5.96e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CCL2—atherosclerosis	8.97e-06	5.94e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	8.95e-06	5.92e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PPARG—atherosclerosis	8.94e-06	5.92e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—NOS3—atherosclerosis	8.89e-06	5.88e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IGF1—atherosclerosis	8.82e-06	5.84e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—MTHFR—atherosclerosis	8.81e-06	5.83e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—INS—atherosclerosis	8.77e-06	5.81e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MMP9—atherosclerosis	8.7e-06	5.76e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CXCL8—atherosclerosis	8.69e-06	5.75e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PPARA—atherosclerosis	8.64e-06	5.72e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MAPK3—atherosclerosis	8.64e-06	5.72e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—NFKB1—atherosclerosis	8.61e-06	5.7e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	8.57e-06	5.67e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—INS—atherosclerosis	8.47e-06	5.61e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MAPK8—atherosclerosis	8.46e-06	5.6e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—AKT1—atherosclerosis	8.44e-06	5.59e-05	CbGpPWpGaD
Prazosin—ADRA2B—GPCR downstream signaling—AKT1—atherosclerosis	8.39e-06	5.55e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	8.38e-06	5.55e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—TGFB1—atherosclerosis	8.38e-06	5.55e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	8.38e-06	5.54e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—AGT—atherosclerosis	8.37e-06	5.54e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	8.34e-06	5.52e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—IL6—atherosclerosis	8.26e-06	5.47e-05	CbGpPWpGaD
Prazosin—SLC22A3—Metabolism—AKT1—atherosclerosis	8.24e-06	5.46e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—APOE—atherosclerosis	8.2e-06	5.43e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	8.19e-06	5.42e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PTGS2—atherosclerosis	8.13e-06	5.38e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—CAV1—atherosclerosis	8.13e-06	5.38e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—APOA1—atherosclerosis	8.11e-06	5.37e-05	CbGpPWpGaD
Prazosin—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	8.1e-06	5.36e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—ALB—atherosclerosis	8.04e-06	5.32e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	8e-06	5.29e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CXCL8—atherosclerosis	7.99e-06	5.29e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—IL6—atherosclerosis	7.97e-06	5.28e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MMP9—atherosclerosis	7.86e-06	5.2e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—VEGFA—atherosclerosis	7.81e-06	5.17e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	7.78e-06	5.15e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—NFKB1—atherosclerosis	7.77e-06	5.15e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—STAT3—atherosclerosis	7.74e-06	5.12e-05	CbGpPWpGaD
Prazosin—ADRA1B—GPCR downstream signaling—AKT1—atherosclerosis	7.71e-06	5.11e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—NOS3—atherosclerosis	7.69e-06	5.09e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MAPK8—atherosclerosis	7.64e-06	5.06e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—AKT1—atherosclerosis	7.62e-06	5.04e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—IL6—atherosclerosis	7.59e-06	5.03e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MMP9—atherosclerosis	7.58e-06	5.02e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	7.5e-06	4.97e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	7.43e-06	4.92e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CG—atherosclerosis	7.4e-06	4.9e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MAPK3—atherosclerosis	7.39e-06	4.89e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	7.38e-06	4.88e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	7.36e-06	4.87e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MMP9—atherosclerosis	7.22e-06	4.78e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—TGFB1—atherosclerosis	7.17e-06	4.75e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—NFKB1—atherosclerosis	7.15e-06	4.73e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PPARG—atherosclerosis	7.14e-06	4.73e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	7.09e-06	4.7e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—VEGFA—atherosclerosis	7.05e-06	4.67e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PTGS2—atherosclerosis	7.04e-06	4.66e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MAPK8—atherosclerosis	7.02e-06	4.65e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—INS—atherosclerosis	7.01e-06	4.64e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—AKT1—atherosclerosis	7e-06	4.64e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—STAT3—atherosclerosis	6.99e-06	4.62e-05	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	6.85e-06	4.54e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	6.81e-06	4.51e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	6.74e-06	4.46e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—STAT3—atherosclerosis	6.74e-06	4.46e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MAPK3—atherosclerosis	6.67e-06	4.42e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	6.59e-06	4.36e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—VEGFA—atherosclerosis	6.49e-06	4.29e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—TGFB1—atherosclerosis	6.47e-06	4.29e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	6.44e-06	4.26e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—ALB—atherosclerosis	6.42e-06	4.25e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—STAT3—atherosclerosis	6.42e-06	4.25e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	6.42e-06	4.25e-05	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	6.37e-06	4.21e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	6.35e-06	4.2e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—IL6—atherosclerosis	6.31e-06	4.18e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	6.27e-06	4.15e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	6.25e-06	4.14e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	6.24e-06	4.13e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	6.22e-06	4.12e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—NOS3—atherosclerosis	6.14e-06	4.07e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MAPK3—atherosclerosis	6.14e-06	4.06e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	5.96e-06	3.95e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—TGFB1—atherosclerosis	5.95e-06	3.94e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	5.9e-06	3.9e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—AKT1—atherosclerosis	5.83e-06	3.86e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	5.8e-06	3.84e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	5.78e-06	3.83e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	5.76e-06	3.81e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	5.7e-06	3.78e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PTGS2—atherosclerosis	5.62e-06	3.72e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	5.45e-06	3.61e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—IL6—atherosclerosis	5.4e-06	3.58e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	5.35e-06	3.54e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	5.3e-06	3.51e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	5.29e-06	3.5e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—AKT1—atherosclerosis	5.22e-06	3.46e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—AKT1—atherosclerosis	5.17e-06	3.42e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	5.06e-06	3.35e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—AKT1—atherosclerosis	4.99e-06	3.3e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	4.91e-06	3.25e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—IL6—atherosclerosis	4.88e-06	3.23e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—AKT1—atherosclerosis	4.82e-06	3.19e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—IL6—atherosclerosis	4.71e-06	3.12e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—AKT1—atherosclerosis	4.5e-06	2.98e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—IL6—atherosclerosis	4.49e-06	2.97e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—AKT1—atherosclerosis	4.35e-06	2.88e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—AKT1—atherosclerosis	4.14e-06	2.74e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—AKT1—atherosclerosis	4.08e-06	2.7e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IL6—atherosclerosis	3.98e-06	2.64e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IL6—atherosclerosis	3.7e-06	2.45e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	3.68e-06	2.43e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—AKT1—atherosclerosis	3.54e-06	2.34e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	3.42e-06	2.26e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—AKT1—atherosclerosis	2.82e-06	1.87e-05	CbGpPWpGaD
